Bardy Diagnostics raises $35.5M Series B led by River Cities to scale CAM heart-monitoring platform
Seattle-based Bardy Diagnostics raised $35.5 million in a Series B round led by River Cities Capital Fund to expand sales, monitoring services, and invest in augmented intelligence and visualization for its Carnation Ambulatory Monitor (CAM), a wearable week-long ECG device used on more than 40,000 patients. The company has now raised $71 million total, employs 90 people, and claims the CAM captures clearer heart rhythms than competing monitors.